To focus on molecular genomics, super-speciality pathology and companion diagnostics
Metropolis Healthcare announced the launch of Metropolis Innovation Cell focusing on molecular genomics, super speciality pathology and companion diagnostics. Under Innovation Cell, Metropolis is introducing various specialized tests related to pregnancy, cancer, infectious diseases and transplant management.
Commenting on the establishment of Metropolis Innovation Cell, Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “As the Innovation and R&D arm of the organisation, Metropolis Innovation Cell will focus on the pursuit of fundamental scientific discoveries to catalyse optimal patient management. This in turn will fuel the company’s vision and mission of being the most trusted scientific brand and delivering inner health information with compassion, expertise, and honesty to proactively engage with patients and clinicians. To further our long-term goals in these areas, we will continue to invest in strengthening our scientific capabilities and expanding our infrastructure to serve patients across the country.”
“Metropolis has always been at the forefront in clinical validation of technologies, tests and platforms that directly ensure an accurate timely diagnosis to the patient, including Digital Pathology (Whole Slide Imaging), FDA-approved Immunotherapy, targeted therapy biomarkers, liquid biopsy, medical genetics, analytical chemistry, pharmacogenomics, COVID diagnostic & prognostic assays etc. After impacting millions of patients, we want to nurture and expand the scope for Oncology, Prenatal testing, Transplant Immunology, Infectious and Chronic Diseases through Next Generation Sequencing and Artificial Intelligence,” says Dr Kirti Chadha, Chief Scientific Officer, Metropolis Healthcare.
